Get started
RocketTickers

CLVS Receives Breakthrough Therapy Designation for Rubraca®

Long
RocketTickers  
NASDAQ:CLVS   None
Beyond Technical Analysis
1
0
beyondta
CLVS: Clovis Oncology, Inc.
2018-10-02 08:00:00
Clovis Oncology Receives Breakthrough Therapy Designation for Rubraca® (rucaparib) for Treatment of BRCA1/2-Mutated Metastatic Castration Resistant Prostate
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.